Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38+0.00 (0.00%)
Close on Nov 18, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Inhibikase Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$65.44M. For fiscal 2025 it was -$51.97M. The highest annual figure on record is -$2.82M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$51.97M | – |
| FY2024 | Dec 31, 2024 | -$28.59M | – |
| FY2023 | Dec 31, 2023 | -$20.09M | – |
| FY2022 | Dec 31, 2022 | -$18.13M | – |
| FY2021 | Dec 31, 2021 | -$14.77M | – |
| FY2020 | Dec 31, 2020 | -$2.82M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$21.05M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.84M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.78M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.77M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.83M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.05M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.78M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.40M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.20M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.33M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.51M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.64M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.64M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.63M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.63M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$663.71K | – |
| Q2 FY2020 | Jun 30, 2020 | -$413.92K | – |
| Q1 FY2020 | Mar 31, 2020 | -$540.02K | – |
See a number that looks wrong?